具有血液凝固活性的质子化基托桑海绵,用于凝血病中的血液静止
Zhenhua Huang1, Dong Zhang1, Laiqiang Tong1
1Engineering Research Center for Biomedical Materials of Ministry of Education, East China University of Science and Technology, Shanghai, 200237, PR China.
Bioactive materials
|August 12, 2024
概括
质子化素 (PCS) 从血蛋白中快速形成蛋白质膜,增强血液静止. 这种新的机制是由酸盐驱动的.
科学领域:
- 生物材料科学 生物材料科学
- 血液静止研究 血液静止研究
- 生物化学 生物化学
背景情况:
- 酸盐 (CS) 是一个有前途的静血材料,但其作用机制尚未完全理解.
- 急性出血管理需要有效的止血剂.
- 质子化素 (PCS) 意外地从血小板贫血 (PPP) 中形成蛋白质膜 (PM).
研究的目的:
- 阐明PCS诱导的PM形成的条件和机制.
- 为了识别PM中的蛋白质,并了解PCS在分子水平上的促凝作用.
- 评估PCS及其衍生物的静血疗效.
主要方法:
- 研究了 -NH3+组在PCS促进凝血中的作用.
- 分析了蛋白质组合,并确定了参与PM形成的凝血因素.
- 通过血液凝结指数 (BCI) 实验和动物出血模型评估静血效果.
主要成果:
- 具有>4.9 mmol/g -NH3+组的PCS显著促进了凝血.
- PCS组装了血蛋白,包括凝血因子 (FII,FV,FX),激活了血细胞,并促进了血小板分泌.
- 在子模型中,PCS95显示出卓越的静血效果,将BCI降低到30多岁的6%左右,显示出95%以上的抗菌活性,并将出血时间降低了70%.
结论:
- 质子化素的静血效应是通过将血蛋白组装成膜来调节的,由其质子化氨基群驱动.
- 这种机制延伸到各种PCS衍生品,为静血材料设计提供了多功能平台.
- 与现有的基托剂相比,PCS具有优越的静血,生物相容性和抗菌性质,为先进的静血解决方案铺平了道路.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
01:05Introduction to Hemostasis
6.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.8K
01:09Coagulation
5.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.7K